Anti–SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report

Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine

“…*P \ 0.05 Our data suggest that immunizing patients with ESKD who have factors favoring humoral immunity with an inactivated SARS-CoV-2 vaccine could achieve similar rates of anti-RBD IgG seroconversion achieved with mRNA-based vaccines. Nevertheless, in comparison to healthy controls, the attenuated humoral immune response to SARS-CoV-2 vaccination in patients with ESKD remained significantly lower[10]. Of note, all healthy controls in our cohort generated anti-RBD IgG seroconversion following a two-dose regimen of an inactivated SARS-CoV-2 vaccine.…”

“…However, data on immunogenicity profiles of an inactivated SARS-CoV-2 vaccine (CoronaVac) in patients undergoing dialysis are limited. Our preliminary report revealed that patients with ESKD receiving dialysis generated a weak antibody response following two doses of the inactivated SARS-CoV-2 vaccine compared to healthy individuals [10]. Moreover, there are concerns that patients with ESKD may not adequately develop protective immunity following immunization with an inactivated SARS-CoV-2 vaccine, as previously observed with the hepatitis B and influenza vaccinations [11][12][13].…”

“…SARS-CoV-2-specific humoral and cell-mediated immune responses of an inactivated wholevirus SARS-CoV-2 vaccine were evaluated at baseline, 4 weeks after the first dose, and 2 weeks after the second dose. Our initial study reported the levels of immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (anti-RBD IgG) using a SARS-CoV-2 immunoglobulin G assay [10]. In the present study, the neutralizing antibody response, which represents the functional effects of the anti-RBD IgG, was assessed using a SARS-CoV-2 surrogate virus neutralization test (sVNT).…”

Antibody responses to inactivated SARS‐CoV‐2 vaccine in peritoneal dialysis patients

“…In an analysis for the use of inactivated vaccine in ESRD patients, 83% seropositivity was reported for PD patients. 9 In a report with the use of mRNA-1273 vaccine, 31 (96.8%) of the 32 PD patients seroconverted after two doses of vaccine, administered 28 days apart. 10 Serologic response in HD patients with mRNA vaccine was around 90%.…”

“…To our knowledge, this is one of the first studies on the effectiveness of inactivated SARS‐CoV‐2 vaccine in PD patients, and 95.6% of our patients could achieve seropositivity. In an analysis for the use of inactivated vaccine in ESRD patients, 83% seropositivity was reported for PD patients 9 . In a report with the use of mRNA‐1273 vaccine, 31 (96.8%) of the 32 PD patients seroconverted after two doses of vaccine, administered 28 days apart 10 .…”